Biosimilars in Europe / / Arnold G Vulto, Steven Simoens, Isabelle Huys, editors.
This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | [Place of publication not identified] : : MDPI - Multidisciplinary Digital Publishing Institute,, 2023. |
Year of Publication: | 2023 |
Language: | English |
Physical Description: | 1 online resource (188 pages) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
LEADER | 02844nam a2200349 i 4500 | ||
---|---|---|---|
001 | 993580985104498 | ||
005 | 20230324024158.0 | ||
006 | m o d | ||
007 | cr ||||||||||| | ||
008 | 230324s2023 xx o 000 0 eng d | ||
020 | |a 3-0365-6574-4 | ||
035 | |a (CKB)5680000000300089 | ||
035 | |a (NjHacI)995680000000300089 | ||
035 | |a (EXLCZ)995680000000300089 | ||
040 | |a NjHacI |b eng |e rda |c NjHacl | ||
050 | 4 | |a HD47.3 |b .B567 2023 | |
082 | 0 | 4 | |a 658.1552 |2 23 |
245 | 0 | 0 | |a Biosimilars in Europe / |c Arnold G Vulto, Steven Simoens, Isabelle Huys, editors. |
264 | 1 | |a [Place of publication not identified] : |b MDPI - Multidisciplinary Digital Publishing Institute, |c 2023. | |
300 | |a 1 online resource (188 pages) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
588 | |a Description based on publisher supplied metadata and other sources. | ||
520 | |a This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries. | ||
546 | |a In English. | ||
505 | 0 | |a About the Editors vii -- Emerging Insights into European Markets of Biologics, Including Biosimilars 1 -- Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019 5 -- Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria 21 -- Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study 31 -- Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany 39 -- Barriers to Biosimilar Prescribing Incentives in the Context of Clinical Governance in Spain 59 -- The Off-Patent Biological Market in Belgium: Is the Health System Creating a Hurdle to Fair Market Competition? 75 -- Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices 81 -- Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review 109 -- Analysis of the Regulatory Science Applied to a Single Portfolio of Eight Biosimilar Product Approvals by Four Key Regulatory Authorities 127 -- Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars 143 -- Informing Patients about Biosimilar Medicines: The Role of European Patient Associations 157. | |
650 | 0 | |a Value analysis (Cost control) | |
650 | 0 | |a cost containment. | |
776 | |z 3-0365-6575-2 | ||
700 | 1 | |a Huys, Isabelle, |e editor. | |
700 | 1 | |a Simoens, Steven, |e editor. | |
700 | 1 | |a Vulto, Arnold G, |e editor. | |
906 | |a BOOK | ||
ADM | |b 2023-04-15 12:27:15 Europe/Vienna |f system |c marc21 |a 2023-02-11 21:29:23 Europe/Vienna |g false | ||
AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5343014080004498&Force_direct=true |Z 5343014080004498 |b Available |8 5343014080004498 |